THE EFFECT OF STATIN USE ON VASCULAR FUNCTION IN HYPERTENSIVE SUBJECTS

他汀类药物的使用对高血压患者血管功能的影响

• 批准号: 7375818
• 负责人: PAMELA OUYANG
• 金额: $ 1.23万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375818
• 关键词: EFFECT; STATIN; USE; VASCULAR; FUNCTION

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypertension, a common risk factor for atherosclerosis, occurs without a known or reversible cause in over 90% of cases, and adjunct strategies are needed to reduce its complications, such as vascular dysfunction. Clinical trials have shown that HMG-CoA reductase inhibitor (statin) therapy reduces cardiovascular mortality and morbidity. This benefit is seen in patients with and without high blood cholesterol levels. Non-lipid actions of statins including effects on the blood vessel wall, the microvasculature and systemic inflammation are likely to be responsible for this benefit. The purpose of this study is to more fully investigate the effects of statins on endothelial dysfunction (both conduit and microvascular), arterial stiffness, inflammation and impaired nitric oxide metabolism, which are potential pathophysiologic mechanisms leading to increased cardiovascular risk in hypertensive individuals.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。高血压是动脉粥样硬化的常见危险因素，在90%以上的病例中，高血压是在没有已知或可逆原因的情况下发生的，需要辅助策略来减少其并发症，如血管功能障碍。临床试验表明，HMG-CoA还原酶抑制剂(他汀类)治疗可降低心血管死亡率和发病率。这一益处在有或没有高胆固醇水平的患者中都能看到。他汀类药物的非脂类作用，包括对血管壁、微血管系统和全身炎症的影响可能是这种益处的原因。本研究的目的是更全面地研究他汀类药物对内皮功能障碍(管道和微血管)、动脉僵硬、炎症和一氧化氮代谢受损的影响，这些都是导致高血压患者心血管风险增加的潜在病理生理机制。